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Introduction
============

Lymph node metastases (LNM) in adults with trunk/extremity soft tissue sarcoma (STS) are rare, generally affecting \< 5% of STS patients \[[@REF1]-[@REF3]\]. However, patients with lymph node involvement have worse overall survival. Several retrospective studies have shown that patients with LNM metastasis have poorer survival \[[@REF3]-[@REF4]\], and the American Joint Commission on Cancer (AJCC) has changed the group staging for lymph node-positive patients with trunk/extremity sarcoma from Stage III to Stage IV. Furthermore, retrospective evidence suggests that lymphadenectomy in patients with LNM from STS is necessary for long-term survival \[[@REF1]-[@REF3], [@REF5]-[@REF7]\]. Thus, it is important to identify patients with STS at high risk for LNM, as these patients may be candidates for pathologic lymph node assessment.

Previous studies defining risk factors for nodal metastasis are primarily based on small, single-institution retrospective studies \[[@REF1], [@REF3], [@REF7]-[@REF8]\]. These series have reported an incidence of lymph node metastasis of 2% - 7%. Reports have also identified several variables associated with the development of lymph node metastasis, including histologic subtype, tumor grade \[[@REF1], [@REF8]-[@REF9]\], patient age \[[@REF2], [@REF8]\], and primary tumor size \[[@REF7]-[@REF8]\].

The aim of this study is to identify risk factors associated with lymph node metastasis in STS patients without distant metastasis using the National Cancer Database (NCDB). We also aimed to identify a clinically relevant high-risk group with an increased risk of harboring disease in regional lymph nodes that may benefit from pathologic LN (lymph node) assessment.

Materials and methods
=====================

The NCDB is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society, which consists of de-identified information regarding patient demographics, tumor characteristics, first-course treatment for the corresponding diagnosis, and survival for approximately 70% of the United States (US) population \[[@REF10]\]. All pertinent cases are reported regularly from CoC-accredited centers and compiled into a unified dataset, which is then validated. The NCDB contains information not included in the Surveillance, Epidemiology, and End Results (SEER) database, including details regarding the use of systemic therapy. The data used in the study were derived from a de-identified NCDB file (2004 - 2015). The American College of Surgeons and the CoC have not verified and are neither responsible for the analytic or statistical methodology employed, nor the conclusions drawn from these data by the investigators. As all patient information in the NCDB database is de-identified, this study was exempt from institutional review board evaluation.

The 2015 NCDB Participant User File contains 96,522 patients with soft tissue sarcoma diagnosed between 2004 and 2015. We included only patients with primary site codes of C471, C472, C476, C478, C479, C491, C492, C496, C498, and C499, corresponding to the ICD-O-3 codes included for trunk/extremity STS via the American Joint Committee on Cancer (AJCC), 8th edition (n = 55,469) \[[@REF11]\]. Other exclusion criteria included distant metastatic disease (n = 8,979), lack of pathologic nodal evaluation (n = 29.684), unknown or discrepant grade (n = 3,231), discordant nodal status and stage group (n = 7), and any patients receiving neoadjuvant therapy or if receipt of neoadjuvant therapy was unknown (n = 2,837). The remaining patients were categorized as either having a pathologically node-positive or node-negative status. Figure [1](#FIG1){ref-type="fig"} shows the Consolidated Standards of Reporting Trials (CONSORT) diagram for the study \[[@REF12]\]. Our final cohort consisted of 10,731 patients, 223 of whom had pathologic lymph node involvement.
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The following disease-related variables were evaluated for association with LN involvement: grade, histology, tumor size, tumor location (trunk vs. extremity), LVI, BI, and neurovascular invasion (NVI). We also included the demographic factors of age, sex, and race. Age was evaluated both as a continuous variable and categorical variable (\< 18 and ≥ 18). The histologies of clear cell, angiosarcoma, rhabdomyosarcoma, and epithelioid (CARE) were grouped as "CARE" histologies, given their higher propensity for LNM as previously described \[[@REF4], [@REF13]\] Other categories for histology included synovial sarcoma, given conflicting reports regarding its association with LNM \[[@REF14]-[@REF16]\], and "other." Univariate comparisons between the LNM cohort and node-negative cohort were made via the Chi-square test. Univariate and logistic regression models were performed to evaluate variables associated with pathologic node positivity. Variables associated with LNM with a P-value \< 0.1 were included in the multivariable logistic regression model using a forward stepwise method, as were variables that were previously shown to have an effect on LNM, such as tumor size \[[@REF7]-[@REF8]\]. Odds ratios and 95% confidence intervals were generated. P-values were derived from two-tailed tests. The analysis was performed using STATA, version 13 (StataCorp LLC, College Station, TX) and P-values \< 0.05 were considered statistically significant.

Results
=======

Ten thousand seven hundred and thirty-one soft tissue sarcoma patients meeting the inclusion criteria were identified which included 10,508 patients without LNM (97.9%) and 223 patients with LNM (2.1%). The cohort characteristics are detailed in Table [1](#TAB1){ref-type="table"}. The LNM cohort had a higher proportion of pediatric cases (16, 7.2%) compared with the node-negative group (235 cases, 2.2%, p \< 0.001), but race was balanced between the node-positive and node-negative cohorts (p = 0.449). The LNM cohort, compared to the node-negative group, had a higher proportion of primary tumors that were in the trunk (47 cases, 21.1% vs. 1,433 cases, 13.6%, p \< 0.001), Grade 3 (198 cases, 88.8% vs. 5,929 cases, 56.4%, p \< 0.001), CARE histology (56 cases, 25.1% vs 458 cases, 4.4%, p \< 0.001), LVI (26 cases, 11.7% vs. 199 cases, 1.9%, p \< 0.001), NVI (7 cases, 3.1% vs. 113 cases, 1.1%, p = 0.008), and BI (10 cases, 4.5% vs. 105 cases, 1.0%, p \< 0.001). The CARE histology category contained 61 (11.9%) clear cell cases, 180 (35.0%) angiosarcoma cases, 139 (27.0%) rhabdomyosarcoma cases, and 134 (26.1%) epithelioid sarcoma cases, and there were 446 cases of synovial sarcoma.

###### Cohort Characteristics for Trunk/Extremity Soft Tissue Sarcoma Patients With or Without Lymph Node Metastasis

  -------------------------------------------------------------------------- --------------- ------ --------------- ------ ----------
  Variable                                                                   Node-negative   \%     Node-positive   \%     P-value
  Total                                                                      10,508          97.9   223             2.1     
  Age (years)                                                                                                              \< 0.001
  \< 18                                                                      235             2.2    16              7.2     
  ≥ 18                                                                       10,237          97.8   207             92.8    
  Sex                                                                                                                      0.999
  Male                                                                       5,654           53.8   120             53.8    
  Female                                                                     4,854           46.2   103             46.2    
  Race                                                                                                                     0.449
  White                                                                      8,743           83.2   183             82.1    
  Black                                                                      1,192           11.3   20              13.5    
  Asian                                                                      283             2.7    7               3.1     
  Unknown                                                                    290             2.8    3               1.4     
  Location                                                                                                                 0.001
  Trunk                                                                      1,433           13.6   47              21.1    
  Extremity                                                                  9,076           86.4   176             78.9    
  Size                                                                                                                     \< 0.001
  ≤ 5 cm                                                                     9.926           94.5   195             87.4    
  \> 5 cm                                                                    52              0.5    4               1.8     
  Unknown                                                                    530             5.0    24              10.8    
  Grade                                                                                                                    \< 0.001
  I                                                                          2,850           27.1   5               2.2     
  II                                                                         1,729           16.5   20              9.0     
  III                                                                        5,929           56.4   198             88.8    
  Histology                                                                                                                \< 0.001
  Clear cell, angiosarcoma, rhabdomyosarcoma, epithelioid (CARE) histology   458             4.4    56              25.1    
  Synovial                                                                   436             4.1    10              4.5     
  Other                                                                      9,614           91.5   157             70.4    
  Lymphovascular Invasion                                                                                                  \< 0.001
  Absent                                                                     2,938           28.0   38              17.0    
  Present                                                                    199             1.9    26              11.7    
  Unknown                                                                    7,371           70.1   159             71.3    
  Neurovascular Invasion                                                                                                   0.008
  Absent                                                                     3,274           31.2   60              26.9    
  Present                                                                    113             1.1    7               3.1     
  Unknown                                                                    7,121           67.8   156             70.0    
  Bone Invasion                                                                                                            \< 0.001
  Absent                                                                     4,722           44.9   117             54.5    
  Present                                                                    105             1.0    10              4.5     
  Unknown                                                                    5,681           54.1   96              43.1    
  -------------------------------------------------------------------------- --------------- ------ --------------- ------ ----------

On univariate analysis (Table [2](#TAB2){ref-type="table"}), older patients and patients with extremity tumors were less likely to have nodal metastasis from STS (OR 0.99, 95% CI 0.986 - 0.999, p = 0.043 and OR 0.59, 95% CI 0.43 - 0.82, p = 0.002, respectively). Race and sex were not associated with nodal positivity (p \> 0.1). High grade (Grade 2 vs. Grade 1, OR 6.59, 95% CI 2.47 - 17.60, p \< 0.001 and Grade 3 vs. Grade 1, OR 19.03, 95% CI 7.83 - 46.29, p \< 0.001), LVI (OR 10.10, 95% CI 6.01 - 16.98, p \< 0.001), NVI (OR 3.38, 95% CI 1.51 - 7.56, p = 0.003), BI (OR 3.84, 95% CI 1.96 - 7.54, p \< 0.001), and tumor size \> 5 cm (OR 3.92, 95% CI 1.40 - 10.93, p = 0.009) were all associated with LNM. CARE histology was also associated with LNM (CARE histology vs. other, OR 7.49, 95% CI 5.44 - 10.3, p \< 0.001), but the synovial sarcoma histology was not (synovial sarcoma vs. other, OR 1.4, 95% CI 0.74 - 2.68, p = 0.666).

###### Univariate and Multivariable Logistic Regression Predicting for Lymph Node Metastasis

CARE: clear cell, angiosarcoma, rhabdomyosarcoma, and epithelioid; CI: confidence interval

  ------------------------- -------------------------------- ---------- ----------------------------------- ----------
  Variable                  Univariate Odds Ratio (95% CI)   P-value    Multivariable Odds Ratio (95% CI)   P-value
  Age (Continuous)          0.993 (0.986 -- 0.999)           0.043      0.99 (0.987 -- 1.001)               0.087
  Sex                                                                   NA                                   
  Male                      Reference                                                                        
  Female                    1.00 (0.77 -- 1.30)              0.999                                           
  Race                                                                  NA                                   
  White                     Reference                                                                        
  Black                     1.20 (0.81 -- 1.78)              0.355                                           
  Asian                     1.18 (0.55 -- 2.54)              0.668                                           
  Unknown                   0.49 (0.16 -- 1.56)              0.228                                           
  Location                                                                                                   
  Trunk                     Reference                                   Reference                            
  Extremity                 0.59 (0.43 -- 0.82)              0.002      0.70 (0.50 -- 0.99)                 0.042
  Size                                                                                                       
  ≤ 5 cm                    Reference                                   Reference                            
  \> 5 cm                   3.92 (1.40 -- 10.93)             0.009      4.12 (1.42 -- 11.99)                0.009
  Unknown                   2.31 (1.50 -- 3.55)              \< 0.001   2.41 (1.52 -- 3.80)                 \< 0.001
  Grade                                                                                                      
  I                         Reference                                   Reference                            
  II                        6.59 (2.47 -- 17.60)             \< 0.001   6.05 (2.26 -- 16.23)                \< 0.001
  III                       19.03 (7.83 -- 46.29)            \< 0.001   15.55 (6.36 -- 38.04)               \< 0.001
  Histology                                                                                                  
  Other                     Reference                                   Reference                            
  CARE                      7.49 (5.44 -- 10.30)             \<0.001    4.72 (3.35 -- 6.66)                 \< 0.001
  Synovial                  1.40 (0.74 -- 2.68)              0.303      0.98 (0.50 -- 1.93)                 0.953
  Lymphovascular Invasion                                                                                    
  Absent                    Reference                                   Reference                            
  Present                   10.10 (6.01 -- 16.98)            \< 0.001   5.86 (3.33 -- 10.31)                \< 0.001
  Unknown                   1.67 (1.17 -- 2.38)              0.005      2.17 (1.43 -- 3.29)                 \< 0.001
  Neurovascular Invasion                                                                                     
  Absent                    Reference                                   Reference                            
  Present                   3.38 (1.51 -- 7.56)              0.003      1.16 (0.47 -- 2.83)                 0.751
  Unknown                   1.20 (0.89 -- 1.61)              0.245      1.71 (1.17 -- 2.51)                 0.006
  Bone Invasion                                                                                              
  Absent                    Reference                                   Reference                            
  Present                   3.84 (1.96 -- 7.54)              \< 0.001   2.73 (1.32 -- 5.61)                 0.006
  Unknown                   0.68 (0.52 -- 0.90)              0.006      0.40 (0.28 -- 0.58)                 \< 0.001
  ------------------------- -------------------------------- ---------- ----------------------------------- ----------

Table [2](#TAB2){ref-type="table"} also shows the multivariable logistic regression analysis. On multivariable analysis, several variables remained associated with LNM. These included Grade 3 tumors (Grade 3 vs. Grade 1, OR 15.55, 95% CI 6.36 - 38.04, p \< 0.001), LVI (OR 5.86, 95% CI 3.33 - 10.31, p \< 0.001,), BI (OR 2.73, 95% CI 1.32 - 5.61, p = 0.006), and tumor size \> 5 cm (OR 4.12, 95% CI 1.42 - 11.99, p = 0.009). CARE histology was also strongly associated with LNM (OR 4.72, 95% CI 3.35 - 6.66, p \< 0.001), while synovial sarcoma was not (OR 0.98, 95% CI 0.50 - 1.93, p = 0.953), and NVI was not associated with LNM on multivariable analysis (p \> 0.1).

Adult patients with Grade 3 tumors and CARE histology were identified as a "high-risk" subset. A total of 402 patients in our cohort were designated as high-risk, and this subset of patients had a greater risk of LNM relative to adult patients without both factors: 11.9% vs. 1.7%, p \< 0.001. Furthermore, high-risk patients with either LVI or BI exhibited an extremely high rate of LNM compared to high-risk patients without LVI or BI (33.3% vs. 9.8%, p \< 0.001) (Figure [2](#FIG2){ref-type="fig"}).
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Discussion
==========

This is the first large scale study of clinical and histologic predictors of LNM in trunk/extremity STS. LN involvement in non-metastatic STS is associated with high-grade, CARE histology, LVI, and BI. High-risk patients - defined as high-grade with CARE histology - have an 11.9% risk of LN involvement and can be considered for pathologic LN assessment, particularly if they exhibit LVI or BI, which increased LNM rates to 33%. Identifying positive lymph nodes in STS may inform prognosis and would likely influence patient management, given the retrospective evidence suggesting a survival benefit for patients with LNM receiving regional lymphadenectomy \[[@REF1]-[@REF3], [@REF5]-[@REF6]\].

The previous studies of LNM in STS primarily evaluated histology and grade as risk factors for nodal involvement \[[@REF1], [@REF3], [@REF7], [@REF16]-[@REF19]\]. To our knowledge, the first study of LNM in STS was published in 1978, where a review of over 3,000 cases of STS identified rhabdomyosarcoma and synovial sarcoma to be associated with increased risk of LNM \[[@REF16]\]. In 1987, a cohort study of 323 patients showed that high-grade, rhabdomyosarcoma histology, and epithelioid histology were associated with LNM \[[@REF7]\]. A larger study of 1,772 patients showed that angiosarcoma, rhabdomyosarcoma, and epithelioid sarcoma had higher rates of LNM \[[@REF3]\]. Another study of 1,066 patients confirmed the previously established risk factors and also showed that clear cell sarcoma increased LNM \[[@REF1]\].

A more recent publication by Keung et al. using the NCDB showed that lymph node positivity had an impact on survival for non-metastatic patients with certain histologic subtypes of sarcoma \[[@REF4]\]. This suggests that pathologic confirmation of nodal disease has a prognostic value, and several retrospective series have shown regional lymphadenectomy to improve survival \[[@REF1]-[@REF3], [@REF5], [@REF6]\]. However, there are no prospective data that show regional lymphadenectomy improves outcomes for patients undergoing surgery for STS. Given the rarity of these tumors and the inherent difficulty of conducting prospective studies, the National Comprehensive Cancer Network (NCCN) has recommended lymphadenectomy for patients with nodal disease based on these retrospective studies. Thus, identifying patients at high-risk for harboring nodal disease is imperative.

This study adds to the current literature by confirming previously identified high-risk histologies and identifying new risk factors for LNM in STS of the trunk/extremity (BI). Furthermore, this study identifies a high-risk cohort with an 11.9% risk of LNM based on factors that can be determined preoperatively with biopsy alone. This high-risk cohort of patients, particularly those with LVI or BI, may benefit from sentinel node biopsy, and, if positive, should be considered for regional lymphadenectomy based on current NCCN recommendations derived from the aforementioned retrospective studies. Of the 223 pathologically node-positive patients in our cohort, only 114 patients were coded as clinically node-positive, 47 patients were coded as clinically node-negative, and the remainder did not have a clinical nodal stage recorded. This suggests that at least 21.1% of the patients (47/223) with nodal disease had no clinical evidence of nodal involvement. It is likely that in some of these cases, nodal metastases were discovered incidentally during resection of a primary tumor, which has been discussed in prior series \[[@REF2], [@REF4]\], but it is possible that some of these patients had a sentinel lymph node biopsy (SLNB). Although the role of SLNB in STS has not yet been determined, a prospective study showed that six of 12 patients with clear cell sarcoma had clinically occult LNM identified by SLNB \[[@REF20]\], which suggests the technique may be useful in patients at high risk for LNM.

A few limitations should be discussed. As is the case in any retrospective review, we may not have been able to control for unknown variables that may have been unbalanced between the cohorts. Furthermore, many of the variables examined had unknown/missing values, including 5.2% of tumor size, 70.2% of LVI, 67.8% of NVI, and 53.8% of BI. We excluded patients who received neoadjuvant therapy to avoid treatment effect on LNM; however, this greatly reduced the number of patients included in the study, including patients likely with larger tumors, given only 56 patients in our cohort had a primary tumor \> 5 cm. Furthermore, the NCDB does not record data for lymph node size, the presence of extracapsular extension, or the type of procedure conducted for lymph node evaluation. We did not evaluate survival in our cohort since we excluded patients receiving neoadjuvant treatment, which is a group with worse prognostic factors and possibly worse overall survival (OS) \[[@REF21]\]. Despite these limitations, this is the largest study of risk factors for LNM in trunk/extremity STS, and the factors identified in this study can be used by practitioners to select patients at high risk for harboring LNM who may benefit from SLNB, even in the absence of clinical evidence of nodal involvement.
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Conclusions
===========

This NCDB study of non-metastatic STS of the trunk and extremity shows that high-grade and CARE histology were associated with pathologically-proven LNM. Adult patients with both features have an overall 11.9% risk of LNM and may be considered for pathologic LN assessment, particularly with the presence of LVI or BI, where the risk of LNM is \> 30%. Patients with proven LNM in the absence of distant metastatic disease can be considered for regional lymphadenectomy based on current NCCN guidelines.
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